^
Association details:
| Biomarker: | TNFAIP3 mutation |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Published date:
11/23/2020
Excerpt:
PCYC-1121 (#NCT01980628) was a phase 2, multi-center, open-label, non-randomized trial designed to assess the efficacy and safety of single-agent ibrutinib in patients with relapsed/refractory MZL….Among 38 patients with SPD data, those with mutations in A20 (TNFAIP3; n = 10) had significantly greater tumor shrinkage than wild type (P = .0117; Figure 4A). Among 24 patients with the extranodal MZL subtype with SPD data, those with mutations in A20 (n = 7) also had significantly greater tumor shrinkage than wild type (P = .0386; Figure 5A).
DOI:
10.1182/bloodadvances.2020003121
Trial ID:
